Nilofer Saba Azad, MD, discusses remaining challenges in colorectal cancer.
Nilofer Saba Azad, MD, associate professor oncology, Johns Hopkins University School of Medicine, director, Developmental Therapeutics Clinical Trials Program, Johns Hopkins Sidney Kimmel Cancer Center, discusses remaining challenges in colorectal cancer (CRC).
Ongoing efforts are spotlighting the importance of cancer screening. As a result, progress is being made in lowering the incidence of CRC, Azad explains.
Additionally, several regulatory approvals in the advanced disease setting have expanded the armamentarium after many years of stagnation, Azad says.
However, despite the addition of these newer agents, patients with advanced CRC continue to derive modest benefits from treatment. Although the survival advantage that these agents have demonstrated in the space is encouraging, additional research needs to be done to make CRC a chronic disease, concludes Azad.